Sign in

Matthew Keeler

MedTech Analyst at Credit Suisse Asset Management Llc/ny

Matthew Keeler is a MedTech Analyst at Credit Suisse, specializing in medical technology equity research with a focus on companies such as Leap Therapeutics and Endologix. He has participated in high-profile industry conferences and earnings calls, providing targeted insights for institutional investors, although specific performance metrics and ranking data are not publicly disclosed. Keeler's career trajectory includes prior senior analyst roles at BNY Mellon Wealth Management, where he was a Senior Healthcare Analyst and previously served as Vice President. He holds professional credentials verified by FINRA, with active securities registrations confirming his authority in equity research analysis.

Matthew Keeler's questions to MCUR leadership

Question · Q2 2015

Matt Keeler from Credit Suisse inquired about the company's commercial expectations, including the timeline to achieve full commercial coverage, and asked how CureXcell's clinical data would resonate with physicians compared to competitors' claims from smaller studies.

Answer

President & CEO Nissim Mashiach outlined a commercial launch timeline for early 2018, following a BLA filing in H2 2016 and a 10-month FDA review. CFO Mark Page noted that dialogue with CMS would begin in 2016. CMO Mike Molyneaux emphasized that their reimbursement cycle would be faster than typical MedTech products due to rigorous FDA-approved trial data. Regarding competition, Dr. Molyneaux stated that physicians view their rigorous Phase III trial as the 'next great hope' and understand its superiority over smaller, non-blinded studies. Mr. Mashiach highlighted CureXcell's ease of use as a key differentiator.

Ask follow-up questions

Fintool

Fintool can predict MCUR logo MCUR's earnings beat/miss a week before the call

Matthew Keeler's questions to LPTX leadership

Question · Q1 2015

Matthew Keeler of Credit Suisse asked for clarification on the upcoming VLU trial futility analysis and inquired about physician feedback on CureXcell's mechanism of action data presented at the Symposium for Advanced Wound Care (SAWC).

Answer

President and CEO Nissim Mashiach explained the futility analysis has three potential outcomes based on probability of success, with the company anticipating a recommendation to continue the trial. Chief Medical Officer Mike Molyneaux added that feedback at SAWC was 'extremely positive,' with physicians excited by the robust and differentiated data presented.

Ask follow-up questions

Fintool

Fintool can predict LPTX logo LPTX's earnings beat/miss a week before the call